Paul L. Nguyen, MD

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.